Dublin, Dec. 20, 2023 (GLOBE NEWSWIRE) -- The "Peripheral Artery Occlusive Disease (PAOD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update" report has ...

The European Medicines Agency (EMA) has published a revised guideline on the development of drugs aimed at treating peripheral arterial occlusive disease (PAOD) in the lower extremities. It will take ...

The baseline characteristics of the patients at initiation of the study were not different between the two treatment groups except for the pain-free walking distance, which was longer in the ...

The European Medicines Agency (EMA) on Thursday released a draft guideline on developing drugs to treat peripheral arterial occlusive disease (PAOD) of the lower extremities. The guideline states that ...

HELSINKI, March 12, 2026 (GLOBE NEWSWIRE)-- Aplagon, a clinical stage biotech pioneering a first-in-class treatment for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic ...

This study aimed to evaluate mid-term outcomes after endovascular repair (EPAR) for popliteal artery aneurysms (PAAs), with a specific focus on identifying prognostic factors for adverse events after ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated, with fewer ...

Imagine putting your socks on one morning and noticing your big toe, which has been painful for a few weeks, has started turning black. A trip to your doctor ends in being referred urgently to a ...

Peripheral artery disease is primarily caused by plaque buildup in your arteries, with risks increased by underlying medical conditions and certain lifestyle factors, but there’s also a possible ...

Peripheral vascular disease (PVD) is a group of conditions involving problems with blood vessels outside your heart and brain. Peripheral arterial disease (PAD) is a type of PVD where your arteries ...

The over-the-counter supplement nicotinamide riboside, a form of vitamin B3, increased the walking endurance of patients with peripheral artery disease, a chronic leg condition for which there are few ...

Clin Drug Invest. 2005;25(2):89-97. At primary endpoint after 6 months of therapy the degree of stenosis and IMT were not significantly different between the treatment groups and no significant ...